Kalvista Pharmaceuticals Inc (KALV) - Total Liabilities
Based on the latest financial reports, Kalvista Pharmaceuticals Inc (KALV) has total liabilities worth $322.93 Million USD as of October 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check KALV asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Kalvista Pharmaceuticals Inc - Total Liabilities Trend (2013–2025)
This chart illustrates how Kalvista Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Kalvista Pharmaceuticals Inc balance sheet assets.
Kalvista Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Kalvista Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shandong Xiantan Co Ltd
SHE:002746
|
China | CN¥3.63 Billion |
|
Glencore PLC
LSE:GLEN
|
UK | GBX99.39 Billion |
|
PMB Technology Bhd
KLSE:7172
|
Malaysia | RM1.16 Billion |
|
Africa Oil Corp
TO:AOI
|
Canada | CA$1.59 Billion |
|
Verusa Holding AS
IS:VERUS
|
Turkey | TL1.18 Billion |
|
Canadian Solar Inc
NASDAQ:CSIQ
|
USA | $10.80 Billion |
|
Navient Corp
NASDAQ:NAVI
|
USA | $46.28 Billion |
|
Oxford Lane Capital Corp
NASDAQ:OXLC
|
USA | $785.40 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Kalvista Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See KALV equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 19.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.95 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kalvista Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kalvista Pharmaceuticals Inc (2013–2025)
The table below shows the annual total liabilities of Kalvista Pharmaceuticals Inc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-04-30 | $155.38 Million | +439.10% |
| 2024-04-30 | $28.82 Million | +29.96% |
| 2023-04-30 | $22.18 Million | +18.04% |
| 2022-04-30 | $18.79 Million | +26.77% |
| 2021-04-30 | $14.82 Million | +68.85% |
| 2020-04-30 | $8.78 Million | -58.97% |
| 2019-04-30 | $21.39 Million | -37.33% |
| 2018-04-30 | $34.14 Million | +1031.08% |
| 2017-04-30 | $3.02 Million | -7.11% |
| 2016-04-30 | $3.25 Million | -50.80% |
| 2016-03-31 | $6.60 Million | -11.72% |
| 2015-12-31 | $7.48 Million | -85.28% |
| 2015-04-30 | $50.83 Million | +351.02% |
| 2014-12-31 | $11.27 Million | -74.28% |
| 2014-04-30 | $43.81 Million | +19.01% |
| 2013-04-30 | $36.81 Million | -- |
About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which … Read more